Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tagraxofusp + pacritinib
- Development stage
- Unknown
- Lead developer
- University of Kansas Medical Center
- Modality
- Small Molecules, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Bacterial Toxin Conjugates → Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral
01
Overview
Tagraxofusp + pacritinib is an investigational combination therapy being evaluated for the treatment of intermediate-II or higher myelofibrosis, particularly in patients who have failed or are ineligible for standard JAK inhibitor therapy. Tagraxofusp (Elzonris) is a recombinant fusion protein consisting of human interleukin-3 (IL-3) fused to a truncated diphtheria toxin; it targets the IL-3 receptor (CD123) expressed on malignant myeloid cells, delivering the toxin to inhibit protein synthesis via ADP-ribosylation of elongation factor 2. Pacritinib (Vonjo) is an oral small molecule inhibitor of Janus kinase 2 (JAK2) and interleukin-1 receptor-associated kinase 1 (IRAK1), approved for myelofibrosis patients with severe thrombocytopenia. The combination is being studied by the University of Kansas Medical Center in the TAGPAC pilot Phase II trial (NCT06414681) to leverage the targeted cytotoxicity of tagraxofusp against CD123-positive cells alongside the JAK2/IRAK1 pathway inhibition of pacritinib.
- Brand names
- ElzonrisVonjo
- Other names
- tagraxofusp-erzs
02
Targets
EEF2 (Eukaryotic elongation factor 2)JAK2 (Janus kinase 2)FLT3 (Fms related receptor tyrosine kinase 3)IRAK1 (Interleukin-1 receptor-associated kinase 1)IL3RA (Interleukin 3 Receptor)
Beyond the preview
Go deeper on tagraxofusp + pacritinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tagraxofusp + pacritinib.